Effectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
SMC Media Srl
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ. © EFIM 2020
Açıklama
Anahtar Kelimeler
COVID-19, Cytokine release syndrome, Tocilizumab
Kaynak
European Journal of Case Reports in Internal Medicine
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
7
Sayı
6
